Use of cytokine polymorphisms and Epstein–Barr virus viral load to predict development of post‐transplant lymphoproliferative disorder in paediatric liver transplant recipients
- 26 May 2006
- journal article
- Published by Wiley in Clinical Transplantation
- Vol. 20 (3) , 389-393
- https://doi.org/10.1111/j.1399-0012.2006.00498.x
Abstract
Abstract: Objective: Currently there are no tests to accurately identify paediatric liver transplant patients at risk for post‐transplant lymphoproliferative disorder (PTLD). Herein we describe the use of cytokine polymorphisms and real‐time quantitative polymerase chain reaction (qPCR) Epstein–Barr virus (EBV) viral load to identify patients at risk for PTLD development.Methods: Between 2001 and 2004, approximately 1047 patient samples were collected for qPCR for EBV in 59 patients. EBV viral load was reported in three groups: low EBV (4000 copies/μg DNA) and biopsy‐proven PTLD. All 59 patients also had cytokine polymorphism genotyping performed for six cytokine polymorphisms (transforming growth factor (TGF)‐β, tumor necrosis factor (TNF)‐α, interleukins (IL)‐6, IL‐10, IL‐2, and interferon (IFN)‐γ) from DNA isolated from peripheral blood mononuclear cells. Positive predictive value (PPV) and negative predictive value (NPV) were calculated using qPCR and cytokine polymorphism results. Data are reported as a mean±standard error of the mean.Results: There were 35 males and 24 females with a mean follow‐up of 34.9 months. EBV viral load had a PPV and NPV of 29 and 95%, respectively. The low IFN‐γ (A/A) polymorphism was found to be present in 4/6 PTLD patients (67%) and only 17/53 (33%) non‐PTLD patients. When the low A/A IFN‐γ polymorphism was combined with EBV viral load for prediction of PTLD, PPV and NPV were 57 and 93%, respectively.Discussion: Use of cytokine genotyping in conjunction with qPCR for EBV viral load can significantly improve the predictive value of diagnostic tests for identification of patients at high risk for PTLD.Keywords
This publication has 13 references indexed in Scilit:
- Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant RecipientsAmerican Journal of Transplantation, 2005
- Cellular Immunity to Epstein-Barr Virus in Liver Transplant Recipients Treated with Rituximab for Post-Transplant Lymphoproliferative DiseaseAmerican Journal of Transplantation, 2005
- Prompt versus preemptive intervention for EBV lymphoproliferative diseaseBlood, 2004
- Epstein‐Barr Virus (EBV) Early‐Antigen Serologic Testing in Conjunction with Peripheral Blood EBV DNA Load as a Marker for Risk of Posttransplantation Lymphoproliferative DiseaseThe Journal of Infectious Diseases, 2003
- Autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for the treatment of persistent active EBV infectionBlood, 2002
- Epstein–Barr virus‐related lymphoproliferation in children after liver transplant: Role of immunity, diagnosis, and managementPediatric Transplantation, 2002
- Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patientsBlood, 2001
- Two novel biallelic polymorphisms in the IL‐2 geneEuropean Journal of Immunogenetics, 1998
- Interleukin‐10 production by a B‐cell line derived from human post‐transplant lymphoproliferative diseaseHematological Oncology, 1995
- Interleukin-6 production in posttransplant lymphoproliferative disease.Journal of Clinical Investigation, 1993